XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Asset Acquisition - Asset Acquisition Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 22, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Asset Acquisition [Line Items]          
Acquired in-process research and development   $ (298) $ 0 $ 130,188 $ 0
Cash acquired       $ 3,035 $ 0
Cost to acquire asset $ 113,200        
Spyre Therapeutics, Inc.          
Asset Acquisition [Line Items]          
Consideration transferred in Series A Preferred Stock and common stock 110,000        
Transaction costs incurred by Aeglea 3,200        
Acquired in-process research and development 130,200        
Cash acquired 3,000        
Assumed liabilities (20,000)        
Cost to acquire asset $ 113,200